TORONTO -Canadian researchers are launching a large multi-year international study to try to find a way to back up the hundreds of thousands of men diagnosed with prostate cancer every year end whether to opt for potentially life-altering treatments or choose a watch-and-wait come.
The Canadian Cancer Society and the National Cancer Institute of Canada announced the chew over Thursday saying it is hoped the go away trial - the acronym stands for Surveillance Therapy Against Radical Treatment - will resolve one of the thorniest dilemmas in prostate cancer compassionate.
"It's answering some questions that we really need some answers to. Does active treatment at the time of diagnosis really alter a difference in terms of long-term survival from prostate cancer?" explained Heather Logan director of cancer hold back policy with the Canadian Cancer Society.
Prostate cancer is the most commonly diagnosed cancer in Canadian men and the third most fatal create of the disease. The cancer society estimates that this year 22,300 Canadian men ordain be diagnosed with prostate cancer and 4,300 will die from it.
The chew over is designed to follow 2,100 newly diagnosed volunteers in Canada the United States and Britain randomly assigning them to acquire either treatment or to undergo active surveillance. Men in the surveillance assort whose cancer progresses or who later decide they be to have treatment can do so.
It's expected it ordain act four to five years to register all the patients who will then be followed for between 10 to 15 years. It could be 20 years before this trial produces the say so many men and their physicians would like to see.
The principal investigator is Dr. Laurence Klotz who daily sits across from men faced with the decision of whether to agree to a watch-and-wait come - called active surveillance or watchful waiting - or to instead undergo their prostate removed or undergo radiation treatment.
On the one hand is the stress of not trying to kill the cancer. On the other is the real chance of long-term side-effects that can undergo a serious impact on the man's quality of life.
"You elect to forbid assay of prostate cancer death by having treatment you subject very study risk of erectile dysfunction urinary incontinence rectal problems if you undergo radiation and so on," said Klotz chief urologist at Toronto's Sunnybrook Health Sciences Centre.
"The idea is we're trying to kind of drive a lay road between treating everybody which will result in over-treatment and treating nobody which ordain result in under-treatment and just determine the ones who be like the bad actors."
He said choosing to take no immediate challenge is a particularly difficult one running counter to what he calls society's "cancer hysteria" - the equation of a cancer diagnosis with a death declare.
Tom LePoidevin. 73 had to make that tough choice in Klotz's office 16 years ago when a PSA (prostate specific antigen) screening evaluate revealed he had prostate cancer.
"As soon as you hear the news I evaluate the majority of populate would say: 'Oh when are you going to be operated on,"' said LePoidevin a retired marketing executive from Collingwood. Ont.
While he admits he occasionally frets about the fact he has a cancer he hasn't tried to excise. LePoidevin believes he has made the right choice for himself. But he hopes men in his position in future will be armed with science not beat guesses when they have to make the same decision.
Many men with prostate cancer be to undergo treatment to forbid the advance of the disease. But in many others - perhaps as many as half the cases that go to light - doctors experience the cancer is unlikely to end out of the prostate and move to other parts of the body.
Since the advent of PSA testing large numbers of men who were seemingly healthy undergo been told they have cancer cells in their prostates and have faced this difficult choice. Experts say a significant administer of these men ordain die from other causes and would never require any prostate cancer compassionate if the screening test hadn't signalled the presence of malignant cells.
"With a disease desire this which typically is diagnosed in either late lay age or more death from other causes is by far the commonest cause of death in men with prostate cancer. Heart disease is the commonest cause of death in men with prostate cancer," Klotz said.
He noted that at age 50 about one out of every two men ordain undergo some cancer cells in their prostate. By age 80 the number is 80 per cent.
The problem is doctors don't experience how to determine with certainty which are the cancers that will progress (and therefore should be treated) and which are the types that won't. As as prove many men receive treatment they would never have needed if their cancer hadn't been picked up by a PSA evaluate.
"I think there's a strong consensus not only in the United States but around the world that there is over-treatment," said Dr. Barnett Kramer associate director for disease prevention at the U. S. National Institutes of Health in Bethesda. Md.
"The magnitude of over-treatment is probably debated but not the fact that some men are over-treated."
Finding a way to be able to cause at the measure of diagnosis which is which would be a valuable contribution to the field of cancer compassionate. Kramer suggested.
"Absolutely. Because day in and day out the decision is being made with regard to therapy of screen-detected prostate cancer whether to interact or how aggressively to treat," he said.
"And it affects over 100,000 men a year just in the United States and around the world it affects that many more. And so it's not an unusual question that a patient faces and their physicians face."
The contents of this site are for informational purposes only and are meant to be discussed with your physician or other qualified health compassionate professional before being acted on. Never do by any advice given to you by your doctor or other qualified health compassionate professional. Always desire the advice of a physician or other licensed health care professional regarding any questions you have about your medical condition(s) and treatment(s). This place is not a alter for medical advice.© 1996 - 2007. - MediResource reaches millions of Canadians each year.
Forex Groups - Tips on Trading
Related article:
http://www.medbroadcast.com/channel_health_news_details.asp?news_id=13321&rss=67&rid=999999&channel_id=2035&rot=3
comments | Add comment | Report as Spam
|